WO2024200637A3 - Schéma posologique d'un inhibiteur d'her2 - Google Patents

Schéma posologique d'un inhibiteur d'her2 Download PDF

Info

Publication number
WO2024200637A3
WO2024200637A3 PCT/EP2024/058464 EP2024058464W WO2024200637A3 WO 2024200637 A3 WO2024200637 A3 WO 2024200637A3 EP 2024058464 W EP2024058464 W EP 2024058464W WO 2024200637 A3 WO2024200637 A3 WO 2024200637A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosing schedule
her2 inhibitor
her2
inhibitor
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2024/058464
Other languages
English (en)
Other versions
WO2024200637A2 (fr
Inventor
Anke Baum
Krzysztof CHYLINSKI
Neil Gibson
Ralph NEUMUELLER
Behbood SADROLHEFAZI
Dirk Scharn
Lukas SCHROETER
Josep Serra
Ute VON WANGENHEIM
Sven WIND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to AU2024247020A priority Critical patent/AU2024247020A1/en
Priority to CN202480032966.5A priority patent/CN121263188A/zh
Priority to KR1020257036057A priority patent/KR20260004349A/ko
Priority to EP24717127.5A priority patent/EP4687907A2/fr
Publication of WO2024200637A2 publication Critical patent/WO2024200637A2/fr
Publication of WO2024200637A3 publication Critical patent/WO2024200637A3/fr
Priority to MX2025011417A priority patent/MX2025011417A/es
Priority to IL323596A priority patent/IL323596A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un schéma posologique d'un inhibiteur d'HER2 utile dans la prévention et/ou le traitement du cancer, en particulier ses doses et son administration en deuxième intention ou plus.
PCT/EP2024/058464 2023-03-29 2024-03-28 Schéma posologique d'un inhibiteur d'her2 Ceased WO2024200637A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2024247020A AU2024247020A1 (en) 2023-03-29 2024-03-28 Dosing schedule of a her2 inhibitor
CN202480032966.5A CN121263188A (zh) 2023-03-29 2024-03-28 Her2抑制剂的给药安排方案
KR1020257036057A KR20260004349A (ko) 2023-03-29 2024-03-28 Her2 억제제의 투여 일정
EP24717127.5A EP4687907A2 (fr) 2023-03-29 2024-03-28 Schéma posologique d'un inhibiteur d'her2
MX2025011417A MX2025011417A (es) 2023-03-29 2025-09-25 Programa de dosificacion de un inhibidor de her.2
IL323596A IL323596A (en) 2023-03-29 2025-09-28 HER2 inhibitor dosing schedule

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP23382299 2023-03-29
EP23382299.8 2023-03-29
EP23383067.8 2023-10-19
EP23383067 2023-10-19
EP23383302.9 2023-12-15
EP23383302 2023-12-15
EP24382331.7 2024-03-27
EP24382331 2024-03-27

Publications (2)

Publication Number Publication Date
WO2024200637A2 WO2024200637A2 (fr) 2024-10-03
WO2024200637A3 true WO2024200637A3 (fr) 2024-12-05

Family

ID=90719285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/058464 Ceased WO2024200637A2 (fr) 2023-03-29 2024-03-28 Schéma posologique d'un inhibiteur d'her2

Country Status (8)

Country Link
EP (1) EP4687907A2 (fr)
KR (1) KR20260004349A (fr)
CN (1) CN121263188A (fr)
AU (1) AU2024247020A1 (fr)
CL (1) CL2025002930A1 (fr)
IL (1) IL323596A (fr)
MX (1) MX2025011417A (fr)
WO (1) WO2024200637A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228858A1 (en) * 2023-12-20 2025-07-17 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213800A1 (fr) * 2020-04-24 2021-10-28 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2009123894A2 (fr) 2008-04-02 2009-10-08 Macrogenics, Inc. Anticorps spécifiques de her2/neu et procédés d’utilisation de ceux-ci

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213800A1 (fr) * 2020-04-24 2021-10-28 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1 June 2022 (2022-06-01), HEYMACH J ET AL: "A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations", XP002811752, Database accession no. EMB-638843082 *
HUANG SIYUAN ET AL: "Effects of the Preparation Process on the Properties of Amorphous Solid Dispersions", AAPS PHARMSCITECH, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 19, no. 5, 18 September 2017 (2017-09-18), pages 1971 - 1984, XP036541906, DOI: 10.1208/S12249-017-0861-7 *
OPDAM F ET AL: "A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, vol. 174, 1 October 2022 (2022-10-01), XP087220539, ISSN: 0959-8049, [retrieved on 20221028], DOI: 10.1016/S0959-8049(22)00811-5 *

Also Published As

Publication number Publication date
KR20260004349A (ko) 2026-01-08
CL2025002930A1 (es) 2026-01-16
AU2024247020A1 (en) 2025-10-30
CN121263188A (zh) 2026-01-02
WO2024200637A2 (fr) 2024-10-03
EP4687907A2 (fr) 2026-02-11
MX2025011417A (es) 2025-11-03
IL323596A (en) 2025-11-01

Similar Documents

Publication Publication Date Title
MX2024005855A (es) Procedimientos para tratar el cancer.
GEP20257811B (en) Pharmaceutical combinations of sos1 inhibitors
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
EP4272818A3 (fr) Agent thrombolytique pour le traitement de la thrombo-embolie
WO2018234568A3 (fr) Hydroxynorkétamine destinée à être utilisée dans le traitement de la dépression
CR20220580A (es) Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
WO2020186132A8 (fr) Traitement d'une crise d'angio-œdème héréditaire avec une dose réduite d'anticorps se liant à la kallicréine plasmatique humaine
ZA202300259B (en) Compound for the treatment of coronaviral infections
MX2025007174A (es) Dispersion solida de un inhibidor de her2
WO2021239935A9 (fr) Anticorps neutralisants contre le coronavirus associé au sars
MX2025007173A (es) Formas cristalinas de un inhibidor de her2
MX2025011417A (es) Programa de dosificacion de un inhibidor de her.2
ZA202406651B (en) Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib
MX2025012183A (es) Formas cristalinas de un inhibidor de ras
MX380070B (es) Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina.
MX2025007170A (es) Esquema de dosificacion de una dispersion solida de un inhibidor de her2
WO2004108062A3 (fr) Prophylaxie et/ou therapie de l'hypertonie portale
MX2022004739A (es) Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo.
PH12021553177A1 (en) Pharmaceutical composition for treating tumor
EP4442315A3 (fr) Inhibiteur de lta4h destiné au traitement ou à la prévention de l'hidrosadénite suppurée
EP3964520A4 (fr) Nouvel oligopeptide et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif
EP2444104A3 (fr) Traitement de la sclerose en plaques (MS) par le campath-1H
WO2025189056A8 (fr) Composés hétérobifonctionnels et leur utilisation dans le traitement d'une maladie
MX2024002566A (es) Regimen de dosificacion para un inhibidor de tead.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2025555927

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/011417

Country of ref document: MX

Ref document number: 2025555927

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 323596

Country of ref document: IL

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025020166

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: AU2024247020

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24717127

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 826323

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 202592804

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2024717127

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2024247020

Country of ref document: AU

Date of ref document: 20240328

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: MX/A/2025/011417

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024717127

Country of ref document: EP

Effective date: 20251029

ENP Entry into the national phase

Ref document number: 2024717127

Country of ref document: EP

Effective date: 20251029

ENP Entry into the national phase

Ref document number: 2024717127

Country of ref document: EP

Effective date: 20251029

ENP Entry into the national phase

Ref document number: 2024717127

Country of ref document: EP

Effective date: 20251029

ENP Entry into the national phase

Ref document number: 2024717127

Country of ref document: EP

Effective date: 20251029

ENP Entry into the national phase

Ref document number: 2024717127

Country of ref document: EP

Effective date: 20251029

ENP Entry into the national phase

Ref document number: 2024717127

Country of ref document: EP

Effective date: 20251029

ENP Entry into the national phase

Ref document number: 2024717127

Country of ref document: EP

Effective date: 20251029

WWP Wipo information: published in national office

Ref document number: 2024717127

Country of ref document: EP